Combination Chemotherapy of Sarcoma 180 with Methotrexate and Bleomycin

Roland T. Skeel, Joseph R. Bertino

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Bleomycin (BLM) and methotrexate are each effective in the treatment of human squamous cell tumors and have different host toxicities. The murine ascites tumor Sarcoma 180, which is also sensitive to each of the drugs alone, was used as a model to see whether a combination of the drugs might be used with therapeutic advantage. Daily treatment with BLM and methotrexate resulted in significant toxicity and little additive therapeutic effect. Sequential treatment with BLM given on Days 1 to 5 and methotrexate given on Days 8 and 9 yielded median survivals no better than those with BLM alone. Treatment with single doses of each drug simultaneously on Day 1 or 2 after inoculation resulted in median survivals that were greater than what would be expected if the effects were additive. Simultaneous treatment was better than when either drug preceded the other by 12 to 24 hr. The results suggest that the clinical trials of the combination would be worthwhile and that simultaneous treatment with each drug would be the preferred schedule for treatment.

Original languageEnglish (US)
Pages (from-to)1028-1031
Number of pages4
JournalCancer Research
Issue number5
StatePublished - May 1973
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combination Chemotherapy of Sarcoma 180 with Methotrexate and Bleomycin'. Together they form a unique fingerprint.

Cite this